Technical Reactions to ARCT Trends in Macro Strategies
This article provides a technical analysis of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) trends and offers AI-generated trading strategies. It highlights a near-term weak sentiment, a mid-channel oscillation, and an exceptional risk-reward short setup. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?
Arcturus Therapeutics (NASDAQ:ARCT) stock recently fell below its two hundred day moving average, trading at $7.51 with a 200-day moving average of $11.80. Despite recent downgrades from several firms, MarketBeat indicates a consensus "Moderate Buy" rating and a $34.00 price target. The company has a market capitalization of $213.36 million, a negative P/E ratio, and high institutional ownership, with Millennium Management significantly increasing its stake.
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its financial results for the fourth quarter and full fiscal year ended December 31, 2025, after the market closes on Tuesday, March 3, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Arcturus is a commercial messenger RNA medicines company focusing on rare disease therapeutics and infectious disease vaccines.
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its financial results for the fourth quarter and full fiscal year ended December 31, 2025, after market close on Tuesday, March 3, 2026. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to provide a corporate update. Arcturus is a commercial messenger RNA medicines company focusing on rare diseases and infectious disease vaccines, known for developing the first self-amplifying mRNA COVID vaccine, KOSTAIVE®.
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating
Citi has lowered its price target for Arcturus Therapeutics Holdings Inc. (ARCT) to $7, while maintaining a neutral rating on the stock. This adjustment reflects a revised outlook on the company's valuation.
Arcturus cut to Neutral at Citi on data for mRNA candidate
Citi has downgraded Arcturus Therapeutics to a Neutral rating from Buy due to data for its mRNA candidate. This ratings change reflects a revised outlook from the analyst firm regarding the company's prospects following recent developments in its drug pipeline.
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics highlighted progress in its mRNA rare disease pipeline at the Guggenheim Biotech Summit. Key updates include advancing its inhaled mRNA candidate for cystic fibrosis (ARCT-032) to a 15 mg daily dose with promising early results, and plans for a larger Phase 2b study with improved endpoints. Additionally, the company is preparing for two FDA Type C meetings in H1 to discuss the regulatory path for its OTC deficiency program (ARCT-810), which has shown significant biomarker effects.
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating
Citi has lowered its price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7 from $9, maintaining a Neutral rating, reflecting caution towards SMID-cap biotech despite seeing opportunities in commercial-stage companies. The decision comes as Arcturus initiates a Phase 1 study for an mRNA-based pandemic influenza vaccine, which could significantly improve its strategic position with positive clinical results. However, Citi suggests that the stock is likely to remain range-bound until clinical data is disclosed.
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating
Citi has revised its price target for Arcturus Therapeutics Holdings Inc. (ARCT) down to $7.00. Despite this reduction, the firm has chosen to maintain a neutral rating on the biotechnology company's stock.
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating
Citi has lowered its price target for Arcturus Therapeutics Holdings Inc. (ARCT) to $7 from $9, maintaining a Neutral rating, citing a selective approach to SMID-cap biotech for 2026. This adjustment follows the initiation of a Phase 1 study for ARCT-2304, a pandemic influenza vaccine, which presents a significant inflection point pending clinical data. The company's future strategic positioning and potential for partnerships depend on positive safety and immunogenicity data from this and future studies.
Trading the Move, Not the Narrative: (ARCT) Edition
This article provides an AI-driven stock analysis for Arcturus Therapeutics Holdings Inc. (ARCT), highlighting a near-term weak sentiment that may lead to a resumption of long-term weakness. It identifies an exceptional short setup with a significant risk-reward ratio and outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) based on multi-timeframe signal analysis. The analysis suggests a potential downside of 46.6% against a minimal risk of 0.3%.
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?
Arcturus Therapeutics (NASDAQ:ARCT) shares recently dropped below their two-hundred-day moving average, trading at $7.02 with a market capitalization of approximately $199.4 million. Despite recent downgrades from several analysts, the company still holds a "Moderate Buy" consensus rating and an average price target of $34.00. Institutional ownership remains high at 94.54%, indicating significant continued interest from large investors.
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets
Roth Capital initiated coverage on Arcturus Therapeutics Holdings Inc. (ARCT) with a Buy rating and a $20 price target, noting that the market essentially prices in zero success for the company's two mid-stage pipeline assets, despite their multi-billion dollar peak sales potential. This discrepancy makes ARCT appear undervalued in the rare disease sector. Separately, Citigroup had previously lowered its price target for ARCT to $7, maintaining a Neutral rating.
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets
Roth Capital recently initiated coverage of Arcturus Therapeutics Holdings Inc. (ARCT) with a Buy rating and a $20 price target, noting that the market is effectively pricing in zero success for the company's mid-stage pipeline assets, which have significant peak sales potential. This makes ARCT potentially one of the most mispriced stocks in rare disease. Meanwhile, Citigroup lowered its price target for ARCT from $9 to $7, maintaining a Neutral rating.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Thirteen brokerages have issued a "Moderate Buy" rating for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), with an average 12-month price target of $34.00. The company recently reported Q3 earnings of -$0.49 per share, beating estimates, and revenue of $17.15 million, with institutional investors holding approximately 94.54% of the stock. Arcturus Therapeutics is a clinical-stage biotechnology company focused on developing mRNA medicines using its STARR® mRNA platform.
(ARCT) Volatility Zones as Tactical Triggers
This article analyzes Arcturus Therapeutics Holdings Inc. (ARCT) with a focus on volatility zones as tactical triggers for trading. It highlights strong near and mid-term sentiment, but a weak long-term outlook, identifying a mid-channel oscillation pattern. The analysis presents an exceptional risk-reward setup targeting an 84.5% gain versus 0.4% risk, alongside three distinct trading strategies tailored for various risk profiles.
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Roth Mkm
Roth Mkm has upgraded Arcturus Therapeutics (NASDAQ:ARCT) to a "strong-buy" rating. Despite the upgrade, overall analyst sentiment remains mixed, and the stock is currently trading significantly below its 200-day simple moving average. Several institutional investors, including Sumitomo Mitsui Trust and Hennion & Walsh, have increased their holdings in the biotechnology company.
Stifel Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $20
Stifel analyst Adam Walsh has initiated coverage on Arcturus Therapeutics (ARCT.US) with a 'buy' rating and set a target price of $20. According to TipRanks data, Walsh has a 45.1% success rate and a 6.3% average return over the past year. This rating is based on an independent third-party analysis provided by TipRanks.
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating
Roth/MKM has initiated coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and a $20.00 price target, citing significant undervaluation despite a 65% stock decline in 2025. The firm believes the biotech company is mispriced given its two mid-stage programs with over $1 billion peak potential each, and strong financial health with cash to fund operations into 2028. This bullish outlook comes despite recent earnings misses and executive leadership changes at Arcturus.
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating
Roth/MKM has initiated coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and a $20 price target, seeing a 163% upside. The firm believes the biotech company is significantly undervalued, trading near its cash value despite having two mid-stage programs with over $1 billion peak potential each, and sufficient cash to fund operations into 2028. This bullish outlook comes despite a substantial stock decline in 2025 and recent earnings that fell below Wall Street expectations.
Price-Driven Insight from (ARCT) for Rule-Based Strategy
This article provides a price-driven insight for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) based on AI models. It highlights a strong near- and mid-term sentiment but a weak long-term outlook, identifying exceptional risk-reward setups. The piece outlines specific trading strategies (Position Trading, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, along with a multi-timeframe signal analysis.
Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility?
Arcturus Therapeutics presented at the J.P. Morgan Healthcare Conference, showcasing its RNA medicines platform and pipeline. While the conference appearance boosts visibility, the company faces ongoing challenges including financial losses, share price volatility, clinical data progress, funding clarity, and concerns from delayed SEC filings and a recent CFO departure. Investor opinions on ARCT vary widely, with fair value estimates between US$9 and US$72, highlighting the divided sentiment and the importance of execution.
FEDERATED HERMES, INC. Reduces Stake in Arcturus Therapeutics Ho
FEDERATED HERMES, INC. reduced its stake in Arcturus Therapeutics Holdings Inc by 29.62%, selling 1,390,420 shares at $6.13 each. While Arcturus appears undervalued with a GF Value of $11.28, its low profitability, financial distress indicated by an Altman Z score of 0.28, and a Piotroski F-Score of 2 warrant a cautious outlook for investors. This strategic move by Federated Hermes suggests a reevaluation of the biotechnology company's future prospects despite a significant post-transaction gain in ARCT's stock price.
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference
Arcturus Therapeutics, a clinical-stage biotechnology company, outlined its near-term clinical and regulatory milestones for its mRNA therapy programs at the J.P. Morgan Conference. The company is advancing an inhaled mRNA therapy (ARCT-810) for cystic fibrosis (CF), planning a Phase 2 study with significant funding from the CF Foundation, and another ARCT-810 program for OTC deficiency, which has moved into Phase 2 in both Europe and the U.S., showing promising biomarker signals. With a leaner operating profile and extended cash runway into 2028, Arcturus aims to achieve key clinical and regulatory alignments in 2026.
ARCT: Advancing mRNA therapies for CF and OTC with strong data, regulatory focus, and solid funding
Arcturus Therapeutics Holdings Inc. (ARCT) is making progress with its mRNA therapies for cystic fibrosis (CF) and OTC deficiency, supported by strong interim clinical data. The company is targeting significant regulatory milestones for 2026 and maintains financial stability to fund its key studies and platform innovation. This information is based on their recent participation in the 44th Annual J.P. Morgan Healthcare Conference.
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Arcturus Therapeutics Holdings Inc. announced that the FDA has granted Fast Track designation for its investigational influenza vaccine candidate, ARCT-2138. This designation aims to expedite the development and review of the vaccine, which targets all four seasonal influenza strains, acknowledging its potential to address an unmet medical need. The company is currently engaged in discussions with regulatory bodies to plan further clinical development.
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics Holdings Inc. announced that its President & CEO, Joseph Payne, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company is a commercial messenger RNA medicines company focusing on rare disease therapeutics and infectious disease vaccines. Arcturus is known for developing KOSTAIVE®, the first self-amplifying mRNA COVID vaccine, and boasts a broad pipeline and extensive patent portfolio for its RNA therapeutic platforms.
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics Holdings Inc. announced that its President & CEO, Joseph Payne, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 5:15 p.m. Pacific Time. The company, a commercial messenger RNA medicines firm, specializes in liver and respiratory rare disease therapeutics and infectious disease vaccines, utilizing its LUNAR and STARR mRNA technologies. Arcturus Therapeutics is known for developing KOSTAIVE®, the first approved self-amplifying mRNA COVID vaccine, and has various collaborations and a pipeline of RNA therapeutic candidates.
(ARCT) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock, highlighting a near-term neutral sentiment but suggesting a pause in mid and long-term weakness. It identifies support and resistance levels and outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also details multi-timeframe signal analysis, providing support and resistance levels for near-term, mid-term, and long-term horizons.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 1-year price target of $36.00, despite several recent downgrades and price target reductions from firms like Piper Sandler and Guggenheim. The company, which is 94.54% institutionally owned, recently beat quarterly EPS estimates but remains unprofitable. Its shares currently trade near $6.25, with institutional investors like Sumitomo Mitsui and Vanguard increasing their positions in Q3.
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones
This article provides a detailed analysis of Arcturus Therapeutics Holdings Inc. (ARCT) for precision trading, highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels. The analysis emphasizes elevated downside risk and offers AI-generated signals for informed trading decisions.
Arcturus Therapeutics Announces CFO Departure and Replacement
Arcturus Therapeutics announced that its CFO, Andy Sassine, will depart by December 31, 2025, receiving a severance package. Joe Roberts, the current Controller, has been appointed as interim CFO without changes to his compensation. The company's stock (ARCT) currently holds a Hold rating with a $7.00 price target, and TipRanks' AI Analyst, Spark, rates it as Neutral due to declining revenues, persistent losses, and a bearish technical trend, despite some positive clinical trial developments.
Arcturus Therapeutics announces CFO transition and interim appointment
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has announced that CFO Andy Sassine will depart on December 31, 2025, a mutual decision not related to company disagreements. Joe Roberts, the company's Controller since March 2024, has been appointed interim principal financial and accounting officer. This leadership change follows the company's recent Q3 2025 financial results, which significantly missed analyst expectations for both EPS and revenue.
Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Arcturus Therapeutics (NASDAQ:ARCT) from "hold" to "sell," aligning with other analysts who have cut ratings and price targets. Despite this, the MarketBeat consensus remains a "Moderate Buy" with an average target of $36.00. The company's stock trades around $7.46, with institutional investors holding approximately 94.5% of the shares, and several hedge funds recently increasing their positions.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus "Moderate Buy" rating from twelve brokerages, with an average 12-month price target of $36.00. The company recently reported an EPS of -$0.49, exceeding analyst estimates, although revenue slightly missed expectations. Despite a high level of institutional ownership, recent downgrades from several firms indicate mixed sentiment.
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics' stock (ARCT) has fallen 59.4% in three months due to mixed interim results from a mid-stage study of its cystic fibrosis drug, ARCT-032. While initial FEV1 results were not significantly positive, AI-assisted HRCT scans showed encouraging reductions in mucus plugs and volume. The company is continuing the phase II study with a higher dose and plans a 12-week efficacy study in early 2026, aiming to address an underserved CF patient population.
Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a commercial messenger RNA medicines company, announced its participation in the Piper Sandler 37th Annual Healthcare Conference. The company will conduct a fireside chat on Tuesday, December 2, 2025, at 12:30 p.m. ET. Arcturus focuses on developing liver and respiratory rare disease therapeutics and infectious disease vaccines.
Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles
Arcturus Therapeutics Holdings Inc. recently hit a new 52-week low of $5.85, reflecting an 81.5% stock price decline over the past year. The company is facing significant financial challenges, including negative return on equity, decreased net sales, and substantial pre-tax profit losses, contrasting sharply with the S&P 500's positive performance. These struggles highlight a difficult period for the microcap pharmaceutical company as it navigates a challenging market landscape.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) reported a Q3 loss of $0.49 per share, significantly beating the Zacks Consensus Estimate of a $1.25 loss, and surpassed revenue estimates with $17.15 million. Despite this positive earnings surprise, the company's shares have underperformed the S&P 500 this year, leading to a Zacks Rank #4 (Sell) due to an unfavorable estimate revisions trend. Investors await management's commentary for future guidance and further revisions to analyst expectations.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. discussed its Q3 2025 earnings and provided updates on its pipeline, including ARCT032 for cystic fibrosis, ARCT810 for OTC deficiency, and vaccine programs. The company highlighted positive interim data for ARCT032 and ARCT810, outlined plans for regulatory meetings and further clinical trials, and detailed financial performance, emphasizing cost reductions to extend its cash runway into 2028. Total operating expenses decreased significantly, driven by lower manufacturing and clinical costs for its COVID and flu programs.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
Pomerantz LLP is investigating potential securities fraud claims against Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) after the company announced disappointing Phase 2 clinical trial results for its cystic fibrosis drug ARCT-032. The investigational inhaled mRNA therapy did not show meaningful improvement in FEV1, causing Arcturus's stock price to fall significantly by over 50% on October 22, 2025. Investors who suffered losses are advised to contact Pomerantz LLP.
Citigroup Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation
Citigroup has maintained a Neutral recommendation for Arcturus Therapeutics Holdings (ARCT). Analyst price forecasts suggest a significant upside of 461.79%, with an average one-year price target of $45.67/share. Institutional ownership in ARCT has increased, with several large funds holding substantial stakes, indicating growing interest despite a bearish put/call ratio.
ARCT ACTIVE INVESTIGATION: Lost Money on Arcturus Therapeutics Holdings Inc.? Contact Levi & Korsinsky Now
Levi & Korsinsky has initiated an investigation into Arcturus Therapeutics Holdings Inc. (ARCT) following a significant drop in its stock price. This decline occurred after the company announced disappointing interim results from a Phase 2 clinical trial for its cystic fibrosis drug candidate, ARCT-032. The firm is investigating potential violations of federal securities laws and encourages affected investors to contact them.
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
Edelson Lechtzin LLP is investigating Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) for potential violations of federal securities laws after the company's stock dropped over 50% following the announcement of unfavorable Phase 2 trial results for its inhaled mRNA therapy ARCT-032. The law firm is encouraging investors with substantial losses to contact them for more information.
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics announced its third-quarter 2025 financial results and pipeline advancements, highlighting encouraging interim Phase 2 data for ARCT-032 in cystic fibrosis and plans to initiate a 12-week safety and preliminary efficacy study in H1 2026. The company also detailed cost reductions to extend its cash runway and provided updates on its ARCT-810 program for OTC deficiency and KOSTAIVE® commercialization with CSL. Financials showed decreased revenues and operating expenses compared to 2024, reporting a net loss of $13.5 million for the quarter.
Arcturus Therapeutics Holdings Inc earnings missed by $6.02, revenue fell short of estimates
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported a significant earnings miss and revenue shortfall for its third quarter. The company posted an EPS of $-0.49, falling $6.02 short of analyst estimates, and revenue of $17.15M, well below the $279.77M consensus estimate. Following these results, the stock price has seen a substantial decline over the last three and twelve months.
Piper Sandler Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation
Piper Sandler has reaffirmed its Overweight recommendation for Arcturus Therapeutics Holdings (ARCT) as of November 11, 2025. Analysts predict a significant upside, with an average one-year price target of $45.67 per share, representing a 420.20% increase from the current price. Fund sentiment indicates a slight increase in institutional ownership, with Federated Hermes and Sumitomo Mitsui Trust Holdings being among the largest shareholders.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arcturus Therapeutics Holdings Inc. (ARCT) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Arcturus Therapeutics Holdings Inc. (ARCT) after the company's stock price dropped significantly. This follows an announcement of interim Phase 2 clinical trial results for ARCT-032, showing no meaningful improvement in a key metric for cystic fibrosis patients. Shareholders are encouraged to contact the firm to learn more and assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arcturus Therapeutics Holdings Inc. (ARCT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Arcturus Therapeutics Holdings Inc. (ARCT) following a significant stock price drop. The investigation stems from interim Phase 2 clinical trial results for ARCT-032, an inhaled mRNA therapy for cystic fibrosis, which failed to show meaningful improvement in FEV1, causing shares to fall over 50%. The firm is encouraging investors who purchased Arcturus securities to learn more about the investigation to assist with potential claims.
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics released its financial results for Q2 2025 and provided updates on its pipeline, highlighting progress in its mRNA therapeutics and vaccines. Key advancements include interim Phase 2 data for ARCT-032 in cystic fibrosis, positive interim data for ARCT-810 in OTC deficiency, and positive Phase 1 results for seasonal flu vaccine candidate ARCT-2138. The company reported a reduced net loss and extended its cash runway into 2028.
